Program
luvometinib
Also written as “luvometinib + anlotinib”, “FCN-159” and “Luvometinib Tablets”.
Its studies are mostly in Neurofibromatosis 1 · Neoplasm Metastasis · Histiocytosis, Langerhans-Cell, led by Fosun Pharma.
Furthest: phase 3, since Jun 6, 20236 company-led studies, 6 open or runningNext primary completion: Apr 30, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fosun Pharma | 66 open or running | phase 3since Jun 6, 2023 | Jun 17, 2021 | Apr 30, 2027phase 3 · NCT07004075 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 17, 2021First study: phase 2 study in Neurofibromatosis 1First studyNCT04954001 · 160 enrolled · United States, China, Spain
- Jun 6, 2023Phase 3 study in Neurofibromatosis 1NCT05913037 · 167 enrolled · China
- Aug 8, 2023Phase 2 study in Histiocytosis, Langerhans-CellNCT05997602 · 56 planned · China
- Jun 3, 2025Phase 2 study in Neurofibromatosis 1NCT07024394 · 65 planned · China
- Jun 3, 2025Phase 3 study in Low-grade GliomaNCT07004075 · 102 planned · China
- Apr 25, 2026Phase 2 study in Neoplasm MetastasisNCT07562581 · 48 planned · China
Ahead
- Apr 30, 2027Primary completion: phase 3 study in Low-grade GliomaNCT07004075
- Jun 2029Primary completion: phase 2 study in Neoplasm MetastasisNCT07562581
- Sep 23, 2029Primary completion: phase 2 study in Neurofibromatosis 1NCT07024394
TargetBeta
MAP2K1 →read by rule
“* Luvometinib is a selective oral MEK1/2 inhibitor.”study text, by rule · the study
Other programs on MAP2K1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cobimetinibrule | Hoffmann-La Roche | phase 3 | 38 |
| pimasertibrule | Merck KGaA, Darmstadt, Germany | phase 2 | 13 |
| mirdametinibrule | Merck KGaA, Darmstadt, Germany | phase 2 | 9 |
| polfurmetinib | Pfizer | phase 1 | 3 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07562581Neoplasm Metastasis · China | 2 | Recruiting | Jun 2029 | 48 |
| NCT07024394Neurofibromatosis 1 · China | 2 | Not yet recruiting | Sep 23, 2029 | 65 |
| NCT07004075Low-grade Glioma · China | 3 | Not yet recruiting | Apr 30, 2027 | 102 |
| NCT05997602Histiocytosis, Langerhans-Cell · China | 2 | Recruiting | May 14, 2025 | 56 |
| NCT05913037Neurofibromatosis 1 · China | 3 | Active, not recruiting | Aug 19, 2025 | 167 |
| NCT04954001Neurofibromatosis 1 · United States, China, Spain | 2 | Active, not recruiting | Feb 28, 2025 | 160 |
How it is read
Names in the registry
- “luvometinib + anlotinib”, 2 entries
- “FCN-159”, 2 entries
- “Luvometinib Tablets”, 1 entry
- “Luvometinib”, 1 entry
- “Test group (Group A): FCN-159 8 mg, orally, once daily;”, 1 entry
Conditions, from the studies’ own filings
- Neurofibromatosis 1, 3 studies
- Neoplasm Metastasis, 1 study
- Histiocytosis, Langerhans-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.